ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies
Newark, DE (Jan. 10, 2020 ) – ANP Technologies Inc. (ANP) and Fulgent Pharma LLC through their partner Moffitt Cancer Center have successfully licensed the rights to develop a novel targeted therapy in the area of leukemia to Celgene (CELG), now Bristol Myers Squibb (BMY), a landmark deal that leverages ANP’s nanotherapeutic platform technology. The partners will work together to develop a new cancer therapy for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). The potential new therapy will target a novel pathway receptor.
The Moffitt research team recently discovered that a specific pathway receptor is up-regulated in MDS and AML malignant cells, and in particular the malignant stem cells, thus offering a potentially favorable disease-specific target for therapies. By utilizing a ligand specific for this pathway receptor along with a covalently linked nanoparticle developed by ANP and licensed to Fulgent Pharma, the team was able to show potential for treating this type of leukemia at the stem cell level.
“Moffitt takes a team approach when it comes to cancer care and research. Our immunology and hematology teams worked together on this novel therapy. We are taking it to the next level, partnering with ANP/Fulgent Pharma to help accelerate translating this discovery from the laboratory to patients in need,” said Jarett Rieger, Sr. Director, Innovation & Industry Alliances of Moffitt.
“With our proprietary nano-delivery and nanotherapeutic technology platform, ANP has successfully developed multiple therapies including nanoencapsulated pactlitaxel, which is currently in clinical and licensed to Fulgent Pharma, as well as a nanoencapsulated antibody cocktail of drugs for the treatment of Ebola infection, which was funded for nonhuman primate testing by the US Department of Defense,” says Dr. Ray Yin, President and CEO of ANP. “The Moffitt collaboration expands our nanotechnology platform and spectrum of drug development, enabling ANP and Fulgent Pharma to develop new targeted therapies to benefit cancer patients.”
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
About ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing innovative nano-therapeutics. In addition to the novel targeted therapy, ANP has also developed nanoencapsulated chemotherapeutics, antibody therapies, immune-oncology and mRNA-based vaccines. Visit ANPTINC.com for more information.
About Fulgent Pharma
Fulgent Pharma is a clinical-stage specialty pharmaceutical company developing oncology therapies that leverage a proprietary nano-drug delivery technology. Fulgent Pharma’s pipeline features three unique drug platforms: nanoencapsulated chemotherapy drugs being developed via the 505(b)(2) pathway, novel targeted therapies, and small molecule based immuno-oncology drugs. The Company’s lead asset, FID-007, is a nanoencapsulated paclitaxel with improved drug solubility and efficacy, as well as decreased toxicity, and is currently tested in clinical trials. Fulgent Pharma was founded in 2015 and is headquartered in Temple City, California. Fulgent Pharma was spun off from Fulgent Genetics, Inc., (NASDAQ:FLGT) a comprehensive genetic testing company, in 2016.
CONTACT:
Greg Witham, MS
302-283-1730
ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies
Newark, DE (Jan. 10, 2020 ) – ANP Technologies Inc. (ANP) and Fulgent Pharma LLC through their partner Moffitt Cancer Center have successfully licensed the rights to develop a novel targeted therapy in the area of leukemia to Celgene (CELG), now Bristol Myers Squibb (BMY), a landmark deal that leverages ANP’s nanotherapeutic platform technology. The partners will work together to develop a new cancer therapy for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). The potential new therapy will target a novel pathway receptor.
The Moffitt research team recently discovered that a specific pathway receptor is up-regulated in MDS and AML malignant cells, and in particular the malignant stem cells, thus offering a potentially favorable disease-specific target for therapies. By utilizing a ligand specific for this pathway receptor along with a covalently linked nanoparticle developed by ANP and licensed to Fulgent Pharma, the team was able to show potential for treating this type of leukemia at the stem cell level.
“Moffitt takes a team approach when it comes to cancer care and research. Our immunology and hematology teams worked together on this novel therapy. We are taking it to the next level, partnering with ANP/Fulgent Pharma to help accelerate translating this discovery from the laboratory to patients in need,” said Jarett Rieger, Sr. Director, Innovation & Industry Alliances of Moffitt.
“With our proprietary nano-delivery and nanotherapeutic technology platform, ANP has successfully developed multiple therapies including nanoencapsulated pactlitaxel, which is currently in clinical and licensed to Fulgent Pharma, as well as a nanoencapsulated antibody cocktail of drugs for the treatment of Ebola infection, which was funded for nonhuman primate testing by the US Department of Defense,” says Dr. Ray Yin, President and CEO of ANP. “The Moffitt collaboration expands our nanotechnology platform and spectrum of drug development, enabling ANP and Fulgent Pharma to develop new targeted therapies to benefit cancer patients.”
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
About ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing innovative nano-therapeutics. In addition to the novel targeted therapy, ANP has also developed nanoencapsulated chemotherapeutics, antibody therapies, immune-oncology and mRNA-based vaccines. Visit ANPTINC.com for more information.
About Fulgent Pharma
Fulgent Pharma is a clinical-stage specialty pharmaceutical company developing oncology therapies that leverage a proprietary nano-drug delivery technology. Fulgent Pharma’s pipeline features three unique drug platforms: nanoencapsulated chemotherapy drugs being developed via the 505(b)(2) pathway, novel targeted therapies, and small molecule based immuno-oncology drugs. The Company’s lead asset, FID-007, is a nanoencapsulated paclitaxel with improved drug solubility and efficacy, as well as decreased toxicity, and is currently tested in clinical trials. Fulgent Pharma was founded in 2015 and is headquartered in Temple City, California. Fulgent Pharma was spun off from Fulgent Genetics, Inc., (NASDAQ:FLGT) a comprehensive genetic testing company, in 2016.
CONTACT:
Greg Witham, MS
302-283-1730
ANP Technologies Achieves ISO 9001:2008 Certification for Quality Management
Newark, DE (March 11, 2013) – ANP Technologies, Inc., a world leader in developing and commercializing various nanobiotechnology-based products for applications related to immunogenicity, biodefense, biologic drug development and therapeutic drug delivery, today announced that it has received the International Organization for Standardization ISO 9001:2008 certification for its quality management system.
ISO 9001:2008 is accepted worldwide as the standard that defines quality. The certification demonstrates ANP’s continued
commitment to meeting the high standards required for the development and manufacturing of assay for biological/chemical
substances and laboratory reagents. ANP‘s quality system was assessed by TUV USA Inc., which conducted multiple audits and
awarded certification in March 2013.
“We believe that receiving ISO 9001:2008 certification is a significant accomplishment and an important milestone as we approach the global commercialization of many of our new products, such as our PEG Immunogenicity ELISA Kit and ACE Acetylcholinesterase Inhibitor Detection Test," said Florence Malinowski, ANP’s Director of Quality Assurance.
“Achieving the ISO 9001:2008 certification reflects our continuous efforts to achieve superior product quality and reliability, and assures our customers that our processes are well-documented and products are well-tested,” said Dr. Ray Yin, president and CTO of ANP.
About ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing and commercializing various nanobiotechnology-based products for applications related to immunogenicity, biodefense, biologic drug development/testing and therapeutic drug delivery.
The U.S. Food and Drug Administration (FDA) has granted approval for ANP Technologies, Inc. and its partner to begin Phase I clinical trials with its first drug – nanoencapsulated paclitaxel.
Newark, DE (February 27, 2018 ) – The U.S. Food and Drug Administration (FDA) has granted approval for ANP Technologies, Inc. and its partner to begin Phase I clinical trials with its first drug – nanoencapsulated paclitaxel. This new broad-spectrum cancer therapy is designed for intravenous (IV) delivery to combat several types of cancer, including breast, lung, ovarian, prostate, and others. Utilizing ANP’s patented nano-drug delivery platform, nanoencapsulated paclitaxel has performed exceptionally well in pre-clinical investigations, boasting similar or better efficacy over existing blockbuster treatment, such as Abraxane (Celgene). “Getting the FDA’s approval is an important validator for our platform drug delivery technology,” explains Dr. Ray Yin, president and CTO of ANP. “It paves the way for ANP to further develop and implement the platform technology in a variety of drug-related applications.”
ANP and its partners have several other drugs in their pipeline, including an antibody cocktail against the Ebola virus, targeted therapies to treat Acute Myeloid Leukemia (AML), as well as several other immune-oncology and mRNA-based vaccine therapies.
About ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing and commercializing various Nano-biotechnology-based products for applications in Nano-therapeutics, immunogenicity testing, chemical and biological defense, medical diagnostics, and food safety testing.
NIDS® COVID-19 Antigen Rapid Test At-Home Use
For Over-the-Counter (OTC) at-Home Use
FDA Emergency Use Authorization (EUA): https://www.fda.gov/media/163318/download
Contact us for more information: Tel.: 302 283 1730 Email: info@anptinc.com
INTRODUCTION:
SARS-CoV-2 (with the disease referred to as COVID-19), was first reported in December 2019. This virus, which causes COVID-19, in addition to SARS and MERS, is among the top three deadly coronaviruses known to man. SARS-CoV-2 is an enveloped, single-stranded RNA virus of the β genus. The virus can trigger mild to severe respiratory illness and has spread rapidly worldwide. The median incubation time of this virus is about 5 days with symptoms manifestation within 14 days of infection. Some of the symptoms of COVID-19 may include fever, cough, shortness of breath, and loss of taste or smell, among others.
To perform the test, a nasal swab patient specimen is extracted in NIDS Antigen swab buffer. The sample mixture is dispensed into the sample well of the device, and test results are interpreted visually at 15 minutes based on the presence or absence of pink/purple-colored lines. Please see the Result Interpretation Illustration below:
The NIDS COVID-19 Antigen Home Test is a rapid lateral flow immunoassay (LFI) intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. The test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years and older with symptoms of COVID-19 within the first 7 days of symptom onset. Please see the Instructions For Use here:
The NIDS COVID-19 Antigen Rapid Test Kit does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein. Antigen is generally detectable in MT nasal swabs during the acute phase of infection. Positive results indicate the presence of viral antigen, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Additional confirmatory testing with a molecular test for positive results may be necessary for results with and without serial testing, if there is a low likelihood of SARS-CoV-2 infection, such as in individuals without known exposures to SARS-CoV-2 or residing in communities with low prevalence of infection. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
Negative results should be treated as presumptive and may be confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. For serial testing programs, additional confirmatory testing with a molecular test for negative results may be necessary, if there is a high likelihood of SARS-CoV-2 infection, such as in an individual with a close contact with COVID-19 or with suspected exposure to COVID-19 or in communities with high prevalence of infection.